Background-Previous reports from our group have shown that 17␤-estradiol reduces the synthesis and activity of inducible nitric oxide synthase (iNOS) in rat aortic smooth muscle cells (SMC) in response to inflammatory mediators. In this study, we investigated the effect of 17␤-estradiol on iNOS function in aortic SMC from streptozotocin-diabetic rats. Methods and Results-Comparative analysis of NO release and of iNOS mRNA and protein content after 24-hour stimulation with a cytokine mixture revealed milder iNOS activation in diabetic than in control SMC. Furthermore, 17␤-estradiol dose-dependently blocked iNOS synthesis and activity in control but not in diabetic SMC. The defective estrogen response in diabetic SMC at 24 hours could not be attributed to reduced expression of estrogen receptors (ER). In fact, mRNA and protein levels of ER␣ and, to a greater extent, of ER␤, were increased in diabetic compared with nondiabetic SMC. Cytokines decreased ER␣ and ER␤ expression in both groups. However, 17␤-estradiol dosedependently restored the expression of ER␣ but further downregulated that of ER␤, indicating a differential regulation of ER isoforms. Conclusions-Estrogenic control of iNOS was impaired in diabetic SMC. This was associated with a larger increase of ER␤ than of ER␣ protein, whereas 17␤-estradiol regulated the two isoforms in an opposite fashion. Thus, modifications in the estrogen modulation of iNOS and in the expression pattern of ER may be involved in diabetic vascular dysfunction. (Circulation. 2003;108:211-217.)
D
iabetes is a cardiovascular disease. 1 Substantial evidence indicates that diabetic vascular dysfunction is associated with marked alterations of nitric oxide (NO) pathways. 2 In the presence of high blood glucose levels, the increased vascular generation of oxygen-derived free radicals, primarily superoxide anions, quenches the biological activity of NO. [2] [3] [4] This may result in a transient increase in NO synthesis through upregulation of endothelial NO synthase (eNOS) in endothelial cells, and even more so through activation of the inducible NOS (iNOS) isoform in smooth muscle cells (SMC) and macrophages. The sustained accumulation of high NO levels generated by iNOS can be toxic through reaction with superoxide to yield peroxynitrite, thereby playing a central role in the pathophysiology of inflammation and oxidant stress. 5 Thus, the iNOS-mediated increase in NO formation may be a major mediator of diabetic vascular dysfunction. Accordingly, functional expression of iNOS has been reported in SMC from the superior mesenteric arteries of rats with chronic diabetes. 6 We previously showed that diabetes impairs vascular function in female streptozotocin-diabetic rats by interfering with NO pathways. 7 In women, diabetes abolishes the gender advantage in cardiovascular risk typical of premenopause. 8 This protection is thought to be mediated, at least in part, by endogenous 17␤-estradiol (E 2 ) through mechanisms still under investigation.
Thus far, two estrogen receptors (ER) have been identified: ER␣ and ER␤. These proteins are encoded by two separate genes, are distinct structurally and functionally, and are expressed in endothelial cells, 9 SMC, 10, 11 and macrophages. 12 In endothelial cells, E 2 increases the expression of eNOS, thereby controlling the tone of underlying SMC, 13 and may also rapidly activate eNOS through ER␣-mediated mechanisms not involving gene expression. 14, 15 Conversely, E 2 blocks the synthesis of iNOS induced by inflammatory stimuli in SMC 11 and macrophages, 12 suggesting that the beneficial effect of the hormone arises from a combined action on different vascular cell types.
The aim of the present study was to further investigate the effects of E 2 on the expression and activity of iNOS in cultured aortic SMC from diabetic rats. In this study, we show that iNOS response to inflammatory events in SMC from diabetic rats is less sensitive to estrogen, probably on account of altered ER␣/ER␤ ratio. These findings indicate possible mechanisms underlying the increased risk of cardiovascular disease in diabetic premenopausal women.
Methods

Materials
E 2 , L-arginine, sepiapterin, ascorbic acid, L-nitroarginine-methyl ester (L-NAME), S-ethylisothiourea (EIT), and streptozotocin (STZ) were obtained from Sigma. The anti-rabbit iNOS polyclonal antibody was purchased from Transduction Laboratories (Lexington, Ky). The anti-ER␣ and anti-ER␤ antibodies were kindly provided by Dr Geoffrey L. Greene (University of Chicago). Oligodeoxynucleotides were synthesized by Amersham Biosciences.
Diabetes Induction
Diabetes was induced by intravenous injection of STZ (65 mg/kg) in male Sprague-Dawley rats weighing 200 to 225 g (Charles River, Calco, Italy). STZ was freshly dissolved in citrate buffer (pH 4.5); control animals were injected with vehicle. Diabetes induction was considered successful when glycosuria was detectable 1 week after treatment. When the animals were killed, they had plasma glucose levels Ͼ25 mmol/L. The procedures followed were in accordance with institutional guidelines of the University of Milan.
Cell Culture
SMC were obtained from aortic intimal-medial layers of nondiabetic and 28-day diabetic rats according to Ross. 16 Cells were grown in medium 199 (M199) as previously described. 11 The medium was replaced with phenol red-free M199 with 10% FCS for 5 days whenever the effects of E 2 were tested. Twenty-four hours before starting experiments, cells were synchronized in medium containing 0.4% FCS. SMC were then incubated for the indicated time with a cytokine mixture comprising 10 ng/mL interleukin-1␤ (IL-1␤), 10 ng/mL interferon-␥ (IFN-␥), 25 ng/mL tumor necrosis factor (TNF)-␣, and 10 g/mL lipopolysaccharide (LPS). We previously demonstrated that this mixture consistently stimulated iNOS protein synthesis in SMC. 11 E 2 and/or other compounds were added along with cytokines.
Gene Expression Analysis
Total RNA was extracted from SMC (2ϫ10 5 cells/well) and rat uterus (as a positive control for ER mRNA expression) with the Bio/RNA-X Cell kit (Bio/Gene, Kimbolton, UK). RNA was reverse transcribed using MMLV reverse transcriptase H(-) (Promega). Amplification of ER␣ and ER␤ cDNAs was carried out with the use of published primer sequences. 11 Amplification of iNOS cDNA was achieved by using the primer pair 5Ј-ATGGCCGACCTGAT-GTTGCC-3Ј (reverse) and 5Ј-TTTGACCAGAGGACCCAGAG-3Ј (forward). The intensity of PCR product bands was normalized to that of the housekeeping gene GADPH by densitometric analysis with the use of the Quantity-One software (Bio-Rad).
Western Blot Analysis
After quantification by Lowry's method, 17 28 g of cell protein was loaded onto discontinuous gradient SDS-PAGE (10% to 5%) gels. After electrophoresis, proteins were transferred to nitrocellulose membrane and incubated first with the primary antibodies (all 1:1000) overnight, then with the peroxidase-conjugated secondary antibody (Bio-Rad) for 1 hour. Proteins were detected by chemiluminescence (Amersham Biosciences).
Nitrite Assay
For nitrite measurement by Griess' reaction, 11 
Statistical Analysis
Data were obtained from at least 3 independent experiments, each value representing meanϮSEM of duplicate or triplicate determinations. Differences between mean values of multiple groups were analyzed by 1-way ANOVA with Fisher's analysis. Values of PϽ0.05 were considered statistically significant.
Results
E 2 Prevents Cytokine-Induced Secretion of Nitrite in SMC From Control But Not From Diabetic Rats
In cultured control SMC exposed to a cytokine mixture for 24 hours, nitrite levels in the medium increased Ϸ4.5-fold (Figure 1 ), 11 but this was significantly opposed by E 2 (10 Ϫ11 to 10 Ϫ9 mol/L). Basal nitrite levels were not affected by E 2 in either group. In SMC from diabetic rats, cytokines increased nitrite production only 2.4-fold, and E 2 did not block cytokine effects but led to a slight dose-dependent increase in nitrite levels (Figure 1 ). This suggests that diabetes induced alterations in SMC metabolism that persisted in the absence of high glucose levels and affected the estrogenic control of nitrite production.
Some vascular dysfunction can be reversed by increasing NOS substrate or adding antioxidants. 2 We then evaluated whether the altered response to cytokine stimulation in diabetic SMC was related to shortage of iNOS substrate or cofactors or to increased oxidant activities. As shown in the Table, addition of increasing concentrations of the iNOS Figure 1 . Effects of E 2 on cytokine-induced nitrite accumulation in culture medium of aortic SMC from control and diabetic rats. SMC were grown in phenol red-free M199 medium for 5 days, synchronized in 0.4% FCS for 24 hours, and stimulated with cytokine cocktail (10 ng/mL IL-1␤, 10 ng/mL IFN-␥, 25 ng/mL TNF-␣, and 10 g/mL LPS) for 24 hours. Increasing concentrations of E 2 (10 Ϫ11 to 10 Ϫ9 mol/L) were added at the same time as cytokines where indicated. Results are meanϮSEM of 6 to 7 independent experiments performed in duplicate. *PϽ0.01 vs untreated; §PϽ0.05 vs untreated diabetic and cytokine-treated control; **PϽ0.01 vs cytokine-treated control; § §PϽ0.05 vs cytokine-treated diabetic (ANOVA).
substrate L-arginine or cofactor sepiapterin did not augment nitrite accumulation in the medium of diabetic SMC, suggesting that those were not limiting steps for iNOS activity. Similarly, addition of either ascorbic acid or lercanidipine (a vascular-selective calcium channel blocker with marked antioxidant properties) failed to affect nitrite production, suggesting that no increased oxidant burden impaired iNOS activity.
In both SMC groups, the cytokine-induced nitrite increase was reversed by the nonselective NOS inhibitor L-NAME and the relatively selective iNOS inhibitor EIT (Figure 2 ), suggesting that it was secondary to iNOS induction. After 24-hour cytokine challenge, nitrite levels were again greater in the media of control SMC than in those of diabetic SMC. However, at 48 hours, nitrite content in the two groups was comparable. Further investigation showed that such differences reflected a distinct temporal pattern of iNOS protein induction. In fact, we consistently measured the highest iNOS protein levels after 48-hour cytokine treatment in diabetic SMC and after 24 hours in control SMC (Figure 3) . After 72 hours, iNOS protein levels decreased, yet were significantly higher than in untreated cells. This delayed response to cytokine stimulation in diabetes was not restricted to isolated SMC but was also observed in whole aortic rings in culture under identical conditions (not shown).
E 2 Exerts Opposite Modulation of iNOS Synthesis in Control and Diabetic SMC
We then evaluated the content of iNOS mRNA and protein after E 2 treatment. As expected, iNOS mRNA was undetectable in untreated SMC from either group, as shown by semiquantitative RT-PCR. In control SMC, cytokine stimulation for 24 hours increased iNOS mRNA content; a modest induction was observed in diabetic SMC as well. However, the overall effect of E 2 was opposite in the two groups. In fact, E 2 (10 Ϫ11 to 10 Ϫ9 mol/L) dose-dependently reduced iNOS mRNA levels in control SMC but increased iNOS mRNA in diabetic SMC severalfold compared with cytokine-treated diabetic and Ϸ2-fold compared with cytokine-treated control SMC (data not shown).
Western blot experiments showed that E 2 reduced in a dose-dependent manner iNOS protein content in cytokinetreated control SMC ( Figure 4A ). By contrast, treatment with E 2 did not affect iNOS protein levels in diabetic SMC despite increased mRNA levels. As shown in Figure 4B , after 48-hour cytokine stimulation, E 2 was about as effective in control as in diabetic SMC at reducing iNOS protein content, indicating that the early difference in response to E 2 between control and diabetic SMC leveled off at later time points. Similar results were obtained for iNOS activity (data not shown). Nitrite production by control and diabetic SMC after 24-hour and 48-hour incubation with cytokines. SMC were grown in M199 mediumϩ10% FCS until confluence, synchronized in 0.4% FCS for 24 hours, and stimulated as described in the legend to Figure 1 for the indicated time in the presence of the NOS inhibitors L-NAME (0.3 mmol/L) and EIT (10 mol/L). Nitrite production was measured in medium aliquots by Griess' reaction. Data are expressed as meanϮSEM of 5 to 7 independent experiments, each performed in duplicate. *PϽ0.01 vs basal; §PϽ0.01 vs cytokines. 
Effects of Different Supplementations on Nitrite Content in Medium of Aortic SMC From Diabetic Rats
Loss of E 2 -Inhibitory Control on iNOS Gene Expression Correlates With Decreased ER␣ and Increased ER␤ Expression
The antithetical control of E 2 on iNOS expression in SMC from diabetic and nondiabetic rats after 24-hour cytokine incubation could not be ascribed to deficiencies in iNOS system. This led us to investigate whether diabetes had altered the expression pattern of ERs. It was apparent that (1) the mRNA of ER␣ was more abundant than that of ER␤ in untreated diabetic and nondiabetic SMC and (2) both ER␣ and ER␤ mRNA levels were consistently greater in diabetic than in control SMC under any condition tested ( Figure 5 ). Cytokine incubation for 24 hours markedly reduced ER␣ mRNA levels, whereas E 2 (10 Ϫ11 to 10 Ϫ9 mol/L) dosedependently restored ER␣ expression in both groups. On cytokine treatment, ER␤ mRNA decreased by Ϸ50% in diabetic SMC and fell to barely detectable levels in control SMC ( Figure 5 ). In sharp contrast to ER␣, E 2 dosedependently reduced ER␤ mRNA in diabetic SMC but had no detectable effect in control SMC.
In contrast to the strong accumulation of ER␣ mRNA in diabetic with respect to nondiabetic SMC, the levels of ER␣ protein were increased by 40% to 50% only ( Figure 6 ). In both SMC groups, cytokines strongly decreased ER␣ levels, and this was dose-dependently reversed by E 2 . Experimental diabetes, on the other hand, had a marked impact on ER␤ protein level, which was Ͼthan 2-fold higher than in nondiabetic SMC. ER␤ content was not affected by cytokine treatment but was significantly diminished by E 2 , particularly in diabetic SMC ( Figure 6 ).
Discussion
In this study we show that the cytokine-mediated iNOS activation and the estrogen response were very different in aortic SMC from diabetic compared with control rats and that this effect was associated with a significant change in ER␣ and ER␤ relative content. These differences may be relevant to diabetic vascular dysfunction.
Data from our group and other groups indicate that the E 2 antagonism to the synthesis of inflammatory proteins is mediated by ER because it occurs in cell cultures at hormone concentrations compatible with ER transcriptional activation, is blocked by specific ER antagonists, and is linked to ER expression. 11, 12, 23, 24 In vitro transfection experiments show that ER is indispensable to E 2 regulation of iNOS transcription. There is little evidence, however, for a direct interaction of estrogen with the iNOS promoter, 25 which lacks canonical estrogen responsive elements. As proposed for the effect of estrogens on other molecules of the inflammatory cascade, it is conceivable that iNOS mRNA synthesis is controlled by ERs by interaction with transcription factors such as NF-B, AP-1, or STATs. 26, 27 Paech et al 28 reported that E 2 has opposite influence on NF-B and AP-1 transcription activity, depending on its association with ER␣ or ER␤. Considering a differential effect of the two ER subtypes on iNOS expression, we propose that the altered ER␣/ ER␤ ratio reported here for diabetic SMC, and in particular the remarkable upregulation of ER␤, underlies the loss of E 2 negative control on iNOS activity. ER␣ and ER␤ expression was increased in diabetic compared with control SMC, with a relative increase in ER␣ and ER␤ protein levels of Ϸ1.4-and 2.5-fold, respectively. Although no experiments were performed in this study to distinguish functionally between ER␣ and ER␤, our findings suggest that the increased ER␤ expression was associated with the defective response to E 2 and to cytokines observed in diabetes. Supporting this hypothesis are recent studies in ER␤-deficient mice describing an important role for ER␤ in regulating vascular function and blood pressure. 29 The authors showed that ER␤ is involved in estrogen-induced accumulation of iNOS protein in endothelium-denuded aortic rings as well as iNOS gene transcription in normal vessels. This lends further support to the view that the altered estrogenic control of iNOS function in diabetic SMC was mediated mainly by ER␤.
The observation that ER␣ and ER␤ protein content was regulated by E 2 in an opposite fashion in aortic SMC ( Figures  5 and 6 ) provides further evidence for the potential divergent effects of the two receptors. 28, 30 By upregulating ER␣, E 2 may enhance the protective antiinflammatory effects mediated by this receptor subtype in these cells while limiting potential proinflammatory effects with ER␤ downregulation. Interestingly, enhanced transcription of both ER subtypes occurred in diabetic cells, although the increase in protein level was more evident for ER␤. It is conceivable that ER protein underwent translational regulation, as was the case for iNOS; this phenomenon has been reported to occur in diabetes. 31, 32 Accordingly, the cytokine-dependent synthesis of iNOS was delayed and significantly blunted in diabetic cells possibly due to altered levels of transcription factors or of intracellular signaling molecules such as intracellular Ca 2ϩ , as suggested by previous studies in SMC. 33 The cytokine response itself was blunted but not abolished in diabetic SMC at the 24-hour time point. Therefore, the altered time course of iNOS response to cytokines and the corresponding loss of estro- genic effect on this phenomenon, along with the changes in the ER expression pattern, appeared to be part of diabetic vascular dysfunction in aortic SMC.
Activation of iNOS in SMC leads to rapid production of high amounts of NO, which causes pathological vasodilation.
In addition, excess NO may interact with superoxide to generate peroxynitrite, which in turn modifies the function of several proteins, contributing to the tissue damage occurring in vascular sepsis and inflammation. 18 Our results may partially explain why diabetes abolishes the gender-specific vascular protection afforded by estrogen reported in epidemiological studies. 8 Thus, understanding the mechanism for the vascular alterations in estrogen response and ER levels in diabetes would be particularly relevant from a clinical perspective. Estrogen inhibits the iNOS activation associated with ovariectomy, 19 uraemia, 20 transplantation, 21 and inflammatory stimuli. 11, 22 Estrogen also appears to be effective in clinical conditions sharing inflammatory features such as multiple sclerosis, Alzheimer's disease, osteoporosis, and periodontitis, indicating that the beneficial effects of estrogen reflect its antiinflammatory action. In view of the possible role of ER␤ in the development of diabetic vascular dysfunction, it would be interesting to assess the role of ER␤ in other inflammatory disorders in which the hormone exerts protective effects. These studies might eventually lead to the development of novel drugs for prevention and treatment of inflammatory disease affecting the aging woman.
